Skip to main content
. 2017 Sep 23;6(11):1997–2008. doi: 10.1002/sctm.17-0091

Figure 1.

Figure 1

Stromal cell‐derived factor‐1 (SDF‐1) is required for ERC‐based therapy in prolongation of cardiac allograft survival. (A): Survival time of cardiac allografts in each B6 recipients receiving different immunosuppressive treatments. Data were shown as percentage of cardiac allograft survival. Statistical analysis was done by Log‐rank (Mantel‐Cox) test. p < .001 (ERCs vs. *ERCs: 19.67 ± 2.58 days vs. 10.17 ± 1.17 days), p < .001, (ERCs + RAPA vs. *ERCs + RAPA: 100 days vs. 28.17 ± 1.72 days). (B): Histology of cardiac allografts in each group of B6 recipients. Grafts were collected at the time of rejection or POD 100, fixed by formalin, and embedded by paraffin. Sections (5 μm) were stained with H&E staining. Cardiac grafts from untreated (Ba), RAPA monotherapy (Bb), ERC monotherapy (Bc), *ERCs (Bd), ERCs‐RAPA combination group (Be), or combination of *ERCs and RAPA (Bf) groups are presented and compared, n = 6. *ERCs indicated inhibition the function of SDF‐1 by AMD3100. Arrows indicate intravascular and/or interstitial changes in cardiac grafts (×400 magnification). Scale bars = 100 μm. Abbreviations: ERC, endometrial regenerative cell; POD, postoperative day; RAPA, rapamycin.